Skip to main content

Halobetasol topical Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Sep 8, 2022.

Halobetasol topical is also known as: Bryhali, Halonate, Lexette, Ultravate

Halobetasol topical Pregnancy Warnings

This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

US FDA pregnancy category: C

Comments: Topical corticosteroids should not be used extensively on pregnant patients, in large amounts or for extended periods of time.

Animal studies have shown the more potent corticosteroids to be teratogenic after dermal application. There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from topically applied corticosteroids.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Halobetasol topical Breastfeeding Warnings

Systemically administered corticosteroids do appear in human milk and could cause adverse effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):

References for breastfeeding information

  1. "Product Information. Ultravate (halobetasol topical)." Apothecon Inc (2022):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.